Objetivo
Congestive Heart failure (CHF) affects more than 15 million European citizens and 1 in 5 people are at risk of developing CHF in their lifetime. It is the leading cause of hospitalizations in patients over 65 years of age, about 1 in 3 patients admitted to hospital will die within one year. CHF accounts for 1-2% (30 Billion €) of healthcare spending in Europe each year. The growth in the numbers of patients developing CHF is driven by the increasing age profile of the EU population and by the growing number of people developing obesity.
Early death and rehospitalization can be reduced dramatically, when the progress of the heart disease is monitored continuously with a wireless pressure sensor, permanently implanted in the patient’s left heart ventricle or left atrium. The implant can provide physicians with detailed real-time information about the patient’s vital functions (intra-cardiac pressure, cardiac output and heart rate) around the clock. Based on those readings, the physician can proactively direct the patient to tweak the medication for stabilizing intra-cardiac pressure and provide early personalized treatments to avoid a crisis that would otherwise lead to hospitalization or even death. No mobile system is available, which allows to continuously and wirelessly monitor the patient’s vital functions during normal daily activities, e.g. (house-)work, sports or outdoor use or during sleep time.
With the strong backgrounds in medicine, medical technology, nano- and micro fabrication as well as engineering and business background of the consortium the first, ultra-small cardiac pressure sensor implant for mobile, continuous 24-7-readout is investigated to be marketed beginning in phase III. One key for success is the incorporation of novel and proven nano-granular materials, which will be fabricated using a proprietary 3D nanoprinting technique (Nano-3D-Sense™) allowing for outstanding performance in miniaturization, biocompatibility and energy efficiency.
Ámbito científico
- medical and health sciencesclinical medicineophthalmologyglaucoma
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health scienceshealth sciencesnutritionobesity
Programa(s)
- H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme
- H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing
- H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEINST-1-2016-2017
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
64283 DARMSTADT
Alemania
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.